Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVD-003 for Congenital Pseudarthrosis of the Tibia
NCT05693558Phase 1Active, not recruiting
- Sponsor
- Novadip Biosciences
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NVD-003 in congenital pseudarthrosis of the tibia (CPT), sponsored by Novadip Biosciences. Primary endpoints: Safety short-term (<=3 months) and Safety mid long-term (>3-12 months). Started Nov 2022; status: active, not recruiting.
02
Drugs
NVD-003
03
Conditions
congenital pseudarthrosis of the tibia (CPT)
Beyond the preview
Go deeper on NCT05693558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693558.